Additionally, we discovered that METTL3 promotes HMGB1 degradation through a m6A-YTHDF2-dependent pathway, inhibits ferroptosis in pancreatic cancer cells, and confers resistance to gemcitabine treatment. This evidence concerns the gene METTL3 and pancreatic neoplasm.